Cheng-Che Chen

Dr. Cheng-Che Chen

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2025 in ACS Nano
Verified
Journal Article
Open access
PLPei-Ying Lin
Pei-Ying Lin
YCYing-Feng Chang
Ying-Feng Chang
CCCheng-Che Chen
Cheng-Che Chen
LSLi-Chen Su
Li-Chen Su
Itamar WillnerItamar Willner
Itamar Willner
AHAnnie Ho
Annie Ho
Bladder cancer (BC) has a high recurrence rate, necessitating frequent monitoring. We herein present an innovative method for detecting BC-related miR-183 and miR-155 microRNAs using pH-responsive triplex DNA nanoswitches (TDNs). This approach employs a stepwise surface plasmon resonance biosensing platform (TDNs-SPR assay) to detect these two miRNAs sequentially. The platform involves the assembly of two triplex pH-responsive probes, switch A (SA) and switch B (SB), on an SPR sensing interface by anchoring the probes to the surface through SA/miR-183 and SB/miR-155 binding to the S9.6 antibody-modified surface. The probes are functionalized with streptavidin-Au nanoparticles/biotinylated strands, which act as reporter units for the presence of the respective miRNAs on the sensing interface. The pH-induced displacement of reporter units triggers stepwise SPR reflectivity changes: at pH 5.0 for sensing miR-183 and at pH 8.3 for sensing miR-155. The reflectivity changes relate quantitatively to the concentrations of miRNAs. This sensing platform enables the detection of two miRNAs with detection limits as low as 0.57 pM for miR-183 and 0.83 pM for miR-155, highlighting its powerful utility for precise biomarker analysis. Moreover, this platform distinguishes BC patients from healthy individuals in urine samples. The method offers a versatile, noninvasive method for detecting any two miRNAs associated with other diseases.

13 January 2023 in Advanced Science
Verified
Journal Article
Open access
CCCheng-Che Chen
Cheng-Che Chen
YFYu‐Chen Fa
Yu‐Chen Fa
YKYen‐Yu Kuo
Yen‐Yu Kuo
YLYi‐Chun Liu
Yi‐Chun Liu
CLChih‐Yu Lin
Chih‐Yu Lin
AHAnnie Ho
Annie Ho
The characteristics of global prevalence and high recurrence of bladder cancer has led numerous efforts to develop new treatments. The spontaneous voiding and degradation of the chemodrug hamper the efficacy and effectiveness of intravesical chemotherapy following tumor resection. Herein, the externally thiolated hollow mesoporous silica nanoparticles (MSN‐SH(E)) is fabricated to serve as a platform for improved bladder intravesical therapy. Enhanced mucoadhesive effect of the thiolated nanovector is confirmed with porcine bladder. The permeation‐enhancing effect is also verified, and a fragmented distribution pattern of a tight junction protein, claudin‐4, indicates the opening of tight junction. Moreover, MSN‐SH(E)‐associated reprogramming of M2 macrophages to M1‐like phenotype is observed in vitro. The antitumor activity of the mitomycin C (MMC)‐loaded nanovector (MMC@MSN‐SH(E)) is more effective than that of MMC alone in both in vitro and in vivo. In addition, IHC staining is used to analyze IFN‐γ, TGF‐β1, and TNF‐α. These observations substantiated the significance of MMC@MSN‐SH(E) in promoting anticancer activity, holding the great potential for being used in intravesical therapy for non‐muscle invasive bladder cancer (NMIBC) due to its mucoadhesivity, enhanced permeation, immunomodulation, and prolonged and very efficient drug exposure.

3 April 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
CCChuan-Shu Chen
Chuan-Shu Chen
JLJian-Ri Li
Jian-Ri Li
SWShian-Shiang Wang
Shian-Shiang Wang
CYCheng-Kuang Yang
Cheng-Kuang Yang
CCChen-Li Cheng
Chen-Li Cheng
Shun-Fa YangShun-Fa Yang
Shun-Fa Yang
The purpose of this study was to identify the significant risk factors of urinary bladder recurrence (UBR) after nephroureterectomy (NUx) in patients with upper tract urothelial carcinoma (UTUC). A total of 550 patients diagnosed with UTUC between January 2001 and December 2015 were included in this retrospective study. The median age of our patients was 68 (range 24–93) and the median follow-up time after NUx was 40.3 months (range 8–191). The most important censored point of this study was the first episode of UBR. Of the 550 patients, UBR occurred in 164 patients (29.8%). One hundred and forty-two (86.6%) patients with UBR were identified within two years after NUx for UTUC, with the median time interval between NUx and UBR being 8.4 months (range 3–59.8). Through univariate analysis, the positive surgical margin (p = 0.049) and tumor multifocality (p = 0.024) were both significant prognostic factors for UBR-free survival after NUx in patients with UTUC. However, only tumor multifocality (p = 0.037) remained a significant prognostic factor by multivariate analysis. In conclusion, tumor multifocality is a significant risk factor of UBR after nephroureterectomy in patients with upper tract urothelial carcinoma.

11 October 2024 in Medicina
Verified
Journal Article
Open access
PDF file
CLChing-Shiang Lin
Ching-Shiang Lin
JLJian-Ri Lee
Jian-Ri Lee
KCKun-Yuan Chiu
Kun-Yuan Chiu
SWShian-Shiang Wang
Shian-Shiang Wang
CCChuan-Shu Chen
Chuan-Shu Chen
CCCheng-Che Chen
Cheng-Che Chen
Background and Objectives: Ureteral reconstruction is aimed at maintaining ureteral patency without the need for long-term catheters like ureteral stents or percutaneous nephrostomies. Different surgical strategies are adopted based on the etiology, the location of the injury, and the severity of the injury. We aimed to analyze the parameters that can predict which patients might not be free from further catheterization after reconstruction. Materials and Methods: This study included patients who underwent ureteral reconstruction from January 2007 to December 2021. The success of ureteral reconstruction was defined as being free from further catheterization after the operation. Results: A total of 184 patients underwent ureteral reconstruction. Malignant disease with ureteral invasion and iatrogenic injuries accounted for 79.9% of the cases. The majority (79.3%) did not have to undergo subsequent interventions. Predictors for a failed result of ureteral reconstruction included a history of radiotherapy (OR = 2.75, p = 0.01), chronic kidney disease (CKD) (OR = 3.42, p < 0.001), and an upper ureteric location of the injury (OR = 5.68, p = 0.042). Conclusions: A history of radiation therapy, an upper third ureteric location of the injury, and CKD were identified as predictors of a failed ureteral reconstruction. Malignant diseases, surgical methods, and repair techniques did not significantly affect the outcome of the operation.

3 December 2023 in Electrochimica Acta
Verified
Journal Article
Closed access
TMTHIRUPPATHI MURUGAN
THIRUPPATHI MURUGAN
NVNithya Velusamy
Nithya Velusamy
CTChing-Ying Tsai
Ching-Ying Tsai
YCYue-Ning Chang
Yue-Ning Chang
CCCheng-Che Chen
Cheng-Che Chen
AHAnnie Ho
Annie Ho

15 March 2019 in IJU Case Reports
Verified
Journal Article
Open access
PDF file
CCCheng-Che Chen
Cheng-Che Chen
GLGu Shun Lai
Gu Shun Lai
CYChii‐Shuenn Yang
Chii‐Shuenn Yang
Introduction: Ureteric bud remnant with renal agenesis is a rare disorder when urogenic system develops. Because of no obvious symptoms, it is usually explored incidentally.Case presentation: A 41‐year‐old male presented with intermittent discharge of turbid fluid from his scrotum. A pinhole was noted in his left scrotum, and an infectious sinus or fistula was impressed. After serial studies, computed tomography revealed agenesis of his left kidney and a cystic lesion over his left scrotum. He underwent resection of the infectious sinus. Near the tail of the sinus, a connection was found to a channel‐like structure. Contrast medium was injected which showed a blind end of this channel‐like structure. The tube was ligated, and the cut end was sent for surgical pathology, which confirmed a left ureteric bud remnant.Conclusion: Complete imaging studies make this diagnosis clearly.